Studies

Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in adults with cystic fibrosis (CF). Traditional management relied on insulin therapy to counter the rise in glucose related to a carbohydrate-rich diet, which was previously reco…

Aims The primary objective of this study is to evaluate the short-term impact of tirzepatide on liver fibrosis markers, specifically the Fibrosis-3 index (FIB-3), Fibrosis-4 index (FIB-4), and aspartate aminotransferase-to-platelet ratio index (APRI)…

Obesity affects a significant proportion of the UK population, and tirzepatide, a dual glucagon-like peptide (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist, is increasingly being prescribed by online services as well as primary car…

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is increasingly prescribed for the treatment of type 2 diabetes and obesity. Although it is generally considered cardiometabo…

Obstructive sleep apnea (OSA) is a prevalent and underdiagnosed sleep disorder strongly associated with obesity. Traditional therapies such as continuous positive airway pressure are effective but often limited by poor adherence. Recent evidence sugg…

Autoimmune thyroid disease (AITD), including Hashimoto thyroiditis and Graves' disease, represents the most prevalent organ-specific autoimmunity and a major cause of thyroid dysfunction worldwide. Increasingly, AITD coexists with metabolic disorders…

Tirzepatide is a long-acting agonist for the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors approved for the treatment of type 2 diabetes mellitus, weight management in obese patients, or overweight patients with a…

: Patients with type 2 diabetes mellitus (T2DM) and inflammatory bowel disease (IBD) face elevated risk of hepatobiliary complications. The biliary safety of GLP-1 and dual GLP-1/GIP receptor agonists in this population is uncertain.: We conducted a…

Each year, over 1 million people in the United States die from diabetes and cardiovascular diseases (CVDs). These largely preventable chronic conditions also create a financial burden on patients, payers, and healthcare systems. The popularity of GLP…

Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, has demonstrated robust efficacy in clinical trials; however, discontinuation rates due to gastrointestinal adverse events have been reported at 6-10% in Western populations. In contrast, our…

The prevalence of type 2 diabetes mellitus has increased drastically over the past century. In the past few years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have gained significant popularity for medical management of type 2 diabetes mellitus…

The introduction of tirzepatide marks a significant advancement in the management of type 2 diabetes mellitus (T2DM) and obesity. This dual synthetic polypeptide, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 recepto…

: Obesity management is evolving with the integration of dual GIP/GLP-1 receptor agonists (Tirzepatide) into comprehensive Digital Weight-Loss Services (DWLSs). This model leverages virtual, app-based multidisciplinary care (MDT) to deliver continuou…

The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) play central roles in metabolic and cardiovascular regulation. GLP-1 receptor agonists (GLP-1RAs) are established therapies for type 2 diabet…

Leptin resistance limits anti-obesity efficacy. We identified a leptin-sensitizing mechanism through tirzepatide (TZP), a glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) dual-agonist. Our tir…

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with limited therapeutic options. Tirzepatide (TZP), a novel dual agonist, has shown promise in metabolic disease, but its effects and mechanisms in NAFLD remain…